An autologous platelet-rich plasma hydrogel compound restores left ventricular structure, function and ameliorates adverse remodeling in a minimally invasive large animal myocardial restoration model: A translational approach. Vu and Pal "Myocardial Repair: PRP, Hydrogel and Supplements"

Biomaterials

Volumn 45, Issue , 2015, Pages 27-35

  Vu, Thang Duc ^a   Pal, Shripad N ^a   Ti, Lian Kah ^a   Martinez, Eliana C ^a   Rufaihah, Abdul Jalil ^a   Ling, Lieng H ^a,b   Lee, Chuen Neng ^a,c   Richards, Arthur Mark ^a,b   Kofidis, Theo ^a,c  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b Dept Medicine Endocrinol Diabet   (Singapore)

^c NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

Author keywords

Antioxidants; Heart failure; Hyaluronic acid based hydrogels; Left ventricular restoration; Myocardial infarction; Platelet rich plasma

Indexed keywords

ANTIOXIDANTS; ASCORBIC ACID; BLOOD VESSELS; CARDIOLOGY; HEART; HYALURONIC ACID; MAMMALS; MUSCLE; PLASMA (HUMAN); PLATELETS; RESTORATION;

ACUTE MYOCARDIAL INFARCTION; ANTI-INFLAMMATORIES; CLINICAL PRACTICES; HEART FAILURE; LEFT VENTRICULAR; MINIMALLY INVASIVE; MYOCARDIAL INFARCTION; PLATELET RICH PLASMA;

HYDROGELS;

ALLOPURINOL; ASCORBIC ACID; COLLAGEN; HYALURONIC ACID; IBUPROFEN; HYDROGEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CORONARY ARTERY CIRCUMFLEX BRANCH; ECHOCARDIOGRAPHY; EXPERIMENTAL PIG; FEMALE; HEART DILATATION; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE WALL; HEART MUSCLE CONTRACTILITY; HEART VENTRICLE REMODELING; HEMODYNAMIC MONITORING; HISTOPATHOLOGY; HOST CELL; HYDROGEL; MINIMALLY INVASIVE PROCEDURE; NONHUMAN; PRIORITY JOURNAL; SCAR; THORACOTOMY; THROMBOCYTE RICH PLASMA; ANGIOGENESIS; ANIMAL; AUTOTRANSPLANTATION; DIASTOLE; DRUG EFFECTS; ECHOGRAPHY; HEART CONTRACTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; HEART VENTRICLE; INJECTION; METABOLISM; MYOCARDIAL INFARCTION; PATHOLOGY; PATHOPHYSIOLOGY; PHARMACOLOGY; PIG; TRANSLATIONAL RESEARCH;

ANIMALIA; SUIDAE;

ANIMALS; CICATRIX; COLLAGEN; DIASTOLE; FEMALE; HEART VENTRICLES; HYDROGEL; INJECTIONS; MYOCARDIAL CONTRACTION; MYOCARDIAL INFARCTION; MYOCARDIUM; NEOVASCULARIZATION, PHYSIOLOGIC; PLATELET-RICH PLASMA; SUS SCROFA; TRANSLATIONAL MEDICAL RESEARCH; TRANSPLANTATION, AUTOLOGOUS; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 84922031820     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.12.013     Document Type: Article

References (45)

1. Sun Y. Myocardial repair/remodelling following infarction: roles of local factors. Cardiovasc Res 2009, 81:482-490.
2. Bursac N., Kirkton R.D., McSpadden L.C., Liau B. Characterizing functional stem cell-cardiomyocyte interactions. Regen Med 2010, 5:87-105.
3. Joggerst S.J., Hatzopoulos A.K. Stem cell therapy for cardiac repair: benefits and barriers. Expert Rev Mol Med 2009, 11. e20.
4. Beitnes J.O., Lunde K., Brinchmann J.E., Aakhus S. Stem cells for cardiac repair in acute myocardial infarction. Expert Rev Cardiovasc Ther 2011, 9:1015-1025.
5. Lin Y.D., Yeh M.L., Yang Y.J., Tsai D.C., Chu T.Y., Shih Y.Y., et al. Intramyocardial peptide nanofiber injection improves postinfarction ventricular remodeling and efficacy of bone marrow cell therapy in pigs. Circulation 2010, 122:S132-S141.
6. Kolettis T.M., Vilaeti A., Dimos K., Tsitou N., Agathopoulos S. Tissue engineering for post-myocardial infarction ventricular remodeling. Mini Rev Med Chem 2011, 11:263-270.
7. Eppley B.L., Woodell J.E., Higgins J. Platelet quantification and growth factor analysis from platelet-rich plasma: implications for wound healing. Plast Reconstr Surg 2004, 114:1502-1508.
8. Carter M.J., Fylling C.P., Parnell L.K. Use of platelet rich plasma gel on wound healing: a systematic review and meta-analysis. Eplasty 2011, 11. e38.
9. Murphy M.B., Blashki D., Buchanan R.M., Yazdi I.K., Ferrari M., Simmons P.J., et al. Adult and umbilical cord blood-derived platelet-rich plasma for mesenchymal stem cell proliferation, chemotaxis, and cryo-preservation. Biomaterials 2012, 33:5308-5316.
10. Suffee N., Richard B., Hlawaty H., Oudar O., Charnaux N., Sutton A. Angiogenic properties of the chemokine RANTES/CCL5. Biochem Soc Trans 2011, 39:1649-1653.
11. Mishra A., Velotta J., Brinton T.J., Wang X., Chang S., Palmer O., et al. RevaTen platelet-rich plasma improves cardiac function after myocardial injury. Cardiovascular revascularization medicine: including molecular interventions 2011, 12:158-163.
12. Li X.H., Zhou X., Zeng S., Ye F., Yun J.L., Huang T.G., et al. Effects of intramyocardial injection of platelet-rich plasma on the healing process after myocardial infarction. Coron Artery Dis 2008, 19:363-370.
13. Wehberg K.E., Answini G., Wood D., Todd J., Julian J., Ogburn N., et al. Intramyocardial injection of autologous platelet-rich plasma combined with transmyocardial revascularization. Cell Transplant 2009, 18:353-359.
14. Cheng K., Li T.S., Malliaras K., Davis D.R., Zhang Y., Marban E. Magnetic targeting enhances engraftment and functional benefit of iron-labeled cardiosphere-derived cells in myocardial infarction. Circ Res 2010, 106:1570-1581.
15. Andia I., Maffulli N. Platelet-rich plasma for managing pain and inflammation in osteoarthritis. Nat Rev Rheumatol 2013, 9:721-730.
16. Shi Y., Evans J.E., Rock K.L. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003, 425:516-521.
17. Kofidis T., Lebl D.R., Swijnenburg R.J., Greeve J.M., Klima U., Robbins R.C. Allopurinol/uricase and ibuprofen enhance engraftment of cardiomyocyte-enriched human embryonic stem cells and improve cardiac function following myocardial injury. Eur J Cardio-thoracic Surg Off J Eur Assoc Cardio-thoracic Surg 2006, 29:50-55.
18. Martinez E.C., Wang J., Gan S.U., Singh R., Lee C.N., Kofidis T. Ascorbic acid improves embryonic cardiomyoblast cell survival and promotes vascularization in potential myocardial grafts invivo. Tissue Eng Part A 2010, 16:1349-1361.
19. Wang T., Wu D.Q., Jiang X.J., Zhang X.Z., Li X.Y., Zhang J.F., et al. Novel thermosensitive hydrogel injection inhibits post-infarct ventricle remodelling. Eur J Heart Fail 2009, 11:14-19.
20. Wollert K.C., Drexler H. Cell therapy for the treatment of coronary heart disease: a critical appraisal. Nat Rev Cardiol 2010, 7:204-215.
21. Tongers J., Losordo D.W., Landmesser U. Stem and progenitor cell-based therapy in ischaemic heart disease: promise, uncertainties, and challenges. Eur Heart J 2011, 32:1197-1206.
22. Kutschka I., Chen I.Y., Kofidis T., Arai T., von Degenfeld G., Sheikh A.Y., et al. Collagen matrices enhance survival of transplanted cardiomyoblasts and contribute to functional improvement of ischemic rat hearts. Circulation 2006, 114:I167-I173.
23. Kofidis T., de Bruin J.L., Yamane T., Tanaka M., Lebl D.R., Swijnenburg R.J., et al. Stimulation of paracrine pathways with growth factors enhances embryonic stem cell engraftment and host-specific differentiation in the heart after ischemic myocardial injury. Circulation 2005, 111:2486-2493.
24. Klopsch C., Furlani D., Gabel R., Li W., Pittermann E., Ugurlucan M., et al. Intracardiac injection of erythropoietin induces stem cell recruitment and improves cardiac functions in a rat myocardial infarction model. JCell Mol Med 2009, 13:664-679.
25. Ke Q., Yang Y., Rana J.S., Chen Y., Morgan J.P., Xiao Y.F. Embryonic stem cells cultured in biodegradable scaffold repair infarcted myocardium in mice. Sheng li xue bao [Acta Physiologica Sinica] 2005, 57:673-681.
26. Mummery C.L., Davis R.P., Krieger J.E. Challenges in using stem cells for cardiac repair. Sci Transl Med 2010, 2. 27ps17.
27. Serban M.A., Scott A., Prestwich G.D. Use of hyaluronan-derived hydrogels for three-dimensional cell culture and tumor xenografts. Current protocols in cell biology/editorial board, Juan S Bonifacino [etal] 2008, Chapter 10:Unit 10 4.
28. Martinez E.C., Kofidis T. Adult stem cells for cardiac tissue engineering. JMol Cell Cardiol 2011, 50:312-319.
29. Pal S.N., Kofidis T. New cell therapies in cardiology. Expert Rev Cardiovasc Ther 2012, 10:1023-1037.
30. Koudstaal S., Bastings M.M., Feyen D.A., Waring C.D., van Slochteren F.J., Dankers P.Y., et al. Sustained delivery of insulin-like growth factor-1/hepatocyte growth factor stimulates endogenous cardiac repair in the chronic infarcted pig heart. JCardiovasc Transl Res 2014, 7:232-241.
31. Arrigoni O., De Tullio M.C. Ascorbic acid: much more than just an antioxidant. Biochim Biophys Acta 2002, 1569:1-9.
32. Dries J.L., Kent S.D., Virag J.A. Intramyocardial administration of chimeric ephrinA1-Fc promotes tissue salvage following myocardial infarction in mice. JPhysiology 2011, 589:1725-1740.
33. He Y.Y., Wen Y., Zheng X.X., Jiang X.J. Intramyocardial delivery of HMGB1 by a novel thermosensitive hydrogel attenuates cardiac remodeling and improves cardiac function after myocardial infarction. JCardiovasc Pharmacol 2013, 61:283-290.
34. Rufaihah A.J., Vaibavi S.R., Plotkin M., Shen J., Nithya V., Wang J., et al. Enhanced infarct stabilization and neovascularization mediated by VEGF-loaded PEGylated fibrinogen hydrogel in a rodent myocardial infarction model. Biomaterials 2013, 34:8195-8202.
35. Ruvinov E., Leor J., Cohen S. The promotion of myocardial repair by the sequential delivery of IGF-1 and HGF from an injectable alginate biomaterial in a model of acute myocardial infarction. Biomaterials 2011, 32:565-578.
36. Somasuntharam I., Boopathy A.V., Khan R.S., Martinez M.D., Brown M.E., Murthy N., et al. Delivery of Nox2-NADPH oxidase siRNA with polyketal nanoparticles for improving cardiac function following myocardial infarction. Biomaterials 2013, 34:7790-7798.
37. Wang J., Huang W., Xu R., Nie Y., Cao X., Meng J., et al. MicroRNA-24 regulates cardiac fibrosis after myocardial infarction. JCell Mol Med 2012, 16:2150-2160.
38. Hu S., Huang M., Li Z., Jia F., Ghosh Z., Lijkwan M.A., et al. MicroRNA-210 as a novel therapy for treatment of ischemic heart disease. Circulation 2010, 122:S124-S131.
39. Kofidis T. Alternative cardiac therapies: stem cells and tissue engineering for the heart. CTSNET 2006, http://archive-org.com/page/1035413/2012-12-22/http://www.ctsnet.org/sections/newsandviews/specialreports/article-4.html.
40. Janssens S. Stem cells in the treatment of heart disease. Annu Rev Med 2010, 61:287-300.
41. Henning R.J. Stem cells in cardiac repair. Future Cardiol 2011, 7:99-117.
42. Telang S., Clem A.L., Eaton J.W., Chesney J. Depletion of ascorbic acid restricts angiogenesis and retards tumor growth in a mouse model. Neoplasia 2007, 9:47-56.
43. Kofidis T., Balsam L.B., Robbins R.C. Afew critical aspects-and Achilles heels-of tissue engineering approaches to restore injured myocardium. JThorac Cardiovasc Surg 2003, 126. 2113-4;author reply 4-6.
44. Kofidis T., Lebl D.R., Martinez E.C., Hoyt G., Tanaka M., Robbins R.C. Novel injectable bioartificial tissue facilitates targeted, less invasive, large-scale tissue restoration on the beating heart after myocardial injury. Circulation 2005, 112:I173-I177.
45. Ifkovits J.L., Tous E., Minakawa M., Morita M., Robb J.D., Koomalsingh K.J., et al. Injectable hydrogel properties influence infarct expansion and extent of postinfarction left ventricular remodeling in an ovine model. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:11507-11512.